Patents by Inventor Aleksander Hinek

Aleksander Hinek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240374618
    Abstract: Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.
    Type: Application
    Filed: November 15, 2023
    Publication date: November 14, 2024
    Inventors: Aleksander HINEK, Thomas F. MITTS
  • Publication number: 20230073764
    Abstract: Compositions, kits, and methods that can be used to improve elastin concentration are described herein. For example, pharmaceutical compositions described herein comprise a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is tannic acid, ellagic acid, or combinations thereof, and the second agent is vitamin D, hyaluronic acid, ferulic acid, or combinations thereof.
    Type: Application
    Filed: May 17, 2022
    Publication date: March 9, 2023
    Inventors: Aleksander HINEK, Thomas F. MITTS
  • Publication number: 20210277072
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Application
    Filed: October 15, 2020
    Publication date: September 9, 2021
    Applicants: ELASTOGENESIS, LLC, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
  • Patent number: 10844101
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: November 24, 2020
    Assignees: Elastogenesis, LLC, The Hospital for Sick Children
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Publication number: 20190153045
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Application
    Filed: November 27, 2018
    Publication date: May 23, 2019
    Applicants: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Patent number: 10167325
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: January 1, 2019
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Patent number: 10004779
    Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: June 26, 2018
    Assignees: Human Matrix Services, LLC, The Hospital for Sick Children
    Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek
  • Patent number: 9867804
    Abstract: Embodiments provide methods for using ascorbate for the stimulation of production of elastic fibers by cells.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: January 16, 2018
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Thomas F. Mitts, Aleksander Hinek, Hyunjun Jonathan Kim
  • Publication number: 20170002047
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Application
    Filed: June 20, 2016
    Publication date: January 5, 2017
    Applicants: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
  • Patent number: 9492462
    Abstract: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: November 15, 2016
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Aleksander Hinek, Thomas Mitts
  • Publication number: 20160303071
    Abstract: Embodiments provide methods for using ascorbate for the stimulation of production of elastic fibers by cells.
    Type: Application
    Filed: June 28, 2016
    Publication date: October 20, 2016
    Applicants: HUMAN MATRIX SCIENCES, LLC, THE HOSPITAL FOR SICK CHILDREN
    Inventors: Thomas F. MITTS, Aleksander HINEK, Hyunjun Jonathan KIM
  • Patent number: 9422334
    Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: August 23, 2016
    Assignees: The Hospital For Sick Children, Human Matrix Sciences, LLC
    Inventors: Felipe Jimenez, Thomas Mitts, Aleksander Hinek
  • Patent number: 9387194
    Abstract: Embodiments provide methods for using ascorbate for the stimulation of production of elastic fibers by cells.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: July 12, 2016
    Assignees: Human Matrix Sciences, LLC, The Hospital For Sick Children
    Inventors: Thomas F. Mitts, Aleksander Hinek, Hyunjun Jonathan Kim
  • Publication number: 20160089415
    Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra- tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
    Type: Application
    Filed: December 8, 2015
    Publication date: March 31, 2016
    Inventors: Thomas MITTS, Felipe JIMENEZ, Aleksander HINEK
  • Patent number: 9283236
    Abstract: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: March 15, 2016
    Assignees: The Hospital for Sick Children, Human Matrix Sciences, LLC
    Inventors: Aleksander Hinek, Thomas F. Mitts
  • Patent number: 9254300
    Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra-tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: February 9, 2016
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek
  • Publication number: 20150359854
    Abstract: Compositions and methods for modulating the deposition of elastin by administering compositions including insulin receptor agonists are described herein.
    Type: Application
    Filed: June 8, 2015
    Publication date: December 17, 2015
    Applicants: THE HOSPITAL FOR SICK CHILDREN, HUMAN MATRIX SCIENCES, LLC
    Inventors: Thomas F. MITTS, Aleksander HINEK
  • Publication number: 20150110755
    Abstract: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.
    Type: Application
    Filed: October 25, 2014
    Publication date: April 23, 2015
    Inventors: Felipe JIMENEZ, Thomas MITTS, Aleksander HINEK
  • Patent number: 9006170
    Abstract: The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: April 14, 2015
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Thomas Mitts, Felipe Jimenez, Aleksander Hinek, Severa Bunda
  • Patent number: 8871707
    Abstract: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: October 28, 2014
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Felipe Jimenez, Thomas F. Mitts, Aleksander Hinek